HDV Screening Study
ConditionHepatitis D Virus Infection
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorGrace Lai Hung Wong
About this trial
This is a territory-wide cross-sectional study of all individuals living with HIV/HBV coinfection and HBV-related HCC.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Individuals with HIV infection, i.e. anti-HIV or HIV RNA positive; AND
Individuals with chronic hepatitis B, i.e. hepatitis B surface antigen (HBsAg) or HBV DNA positive for two times at least 6 months apart; AND
Aged 18 years old or above.
Written or verbal consent obtained
Disqualifiers
Refusal to consent
Age < 18 years
Trial population
Individuals living with HIV/HBV coinfection and HBV-related HCC
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Rate of positive anti-HDV
Primary endpoint is seroprevalence rate of positive anti-HDV
Time frame
at screeningSecondary outcomes
1
Prevalence rate of detectable HDV RNA
Prevalence rate of detectable HDV RNA
Time frame
at screening2
Prevalence rate of compensated advanced chronic liver disease
Prevalence rate of compensated advanced chronic liver disease (cACLD) defined as a liver stiffness measurement above 10.0 kPa
Time frame
at screeningSponsors and contacts
Click on the lead sponsor to view all of their trials.
Grace Lai Hung Wong
Lead sponsor
Chinese University of Hong Kong
Sponsor institution
Gilead Sciences
Collaborator
Source ClinicalTrials.gov